These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 4384559)

  • 21. Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. I. Experimental findings in guinea pigs.
    Dworski M
    Am Rev Respir Dis; 1973 Aug; 108(2):294-300. PubMed ID: 4578541
    [No Abstract]   [Full Text] [Related]  

  • 22. Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections.
    Malhotra P; Farber BF
    Can J Urol; 2011 Jun; 18(3):5671-5. PubMed ID: 21703038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of isoniazid on BCG-mediated tumor immunity.
    Romolo JL; Loyd B; Cohen MH
    Surg Forum; 1977; 28():158-9. PubMed ID: 364713
    [No Abstract]   [Full Text] [Related]  

  • 24. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
    Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
    Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Studies on INH resistant BCG bacillus].
    NAGATA S
    Kekkaku; 1958 Oct; 33(10):699-702; English abstract 707. PubMed ID: 13611846
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of bacillus Calmette-Guérin and isoniazid-resistant bacillus Calmette-Guérin with and without isoniazid chemoprophylaxis from day of vaccination. II. Field trial in man.
    Vandiviere HM; Dworski M; Melvin IG; Watson KA; Begley J
    Am Rev Respir Dis; 1973 Aug; 108(2):301-13. PubMed ID: 4578542
    [No Abstract]   [Full Text] [Related]  

  • 27. Primary isoniazid resistance in Mycobacterium bovis disease: a prospect of concern.
    McLaughlin AM; Gibbons N; Fitzgibbon M; Power JT; Foley SC; Hayes JP; Rogers T; Keane J
    Am J Respir Crit Care Med; 2012 Jul; 186(1):110-1. PubMed ID: 22753693
    [No Abstract]   [Full Text] [Related]  

  • 28. An enzyme system of Mycobacterium tuberculosis that reacts specifically with isoniazid. I.
    Youatt J; Tham SH
    Am Rev Respir Dis; 1969 Jul; 100(1):25-30. PubMed ID: 4307733
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug resistance in the Swedish/Norwegian BCG strain.
    Hesselberg I
    Bull World Health Organ; 1972; 46(4):503-7. PubMed ID: 4559464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of pyruvate medium for isolation of M. bovis and M. tuberculosis resistant to INH.
    Naganathan N; Rajalakshmi R
    Indian J Med Res; 1977 Oct; 66(4):556-61. PubMed ID: 415971
    [No Abstract]   [Full Text] [Related]  

  • 31. [Studies on the resistant BCG strain to isonicotinic acid hydrazid (INH). III. Immunogenicity of resistant BCG strain to INH].
    NAGATA S
    Kekkaku; 1959 Jan; 34(1):7-10; English abstract 54. PubMed ID: 13631843
    [No Abstract]   [Full Text] [Related]  

  • 32. "Broadband" proteomics tackles TB.
    Thompson AH
    J Proteome Res; 2006 Jan; 5(1):13. PubMed ID: 16435444
    [No Abstract]   [Full Text] [Related]  

  • 33. The antimycobacterial activity of rifampin.
    Hobby GL; Lenert TF
    Am Rev Respir Dis; 1968 Apr; 97(4):713-4. PubMed ID: 4966953
    [No Abstract]   [Full Text] [Related]  

  • 34. [Microbacterial resistance to antibiotic preparations].
    Savchenko PIu
    Mikrobiol Zh; 1970; 32(3):376-82. PubMed ID: 4996138
    [No Abstract]   [Full Text] [Related]  

  • 35. Radiometric studies on the use of selective inhibitors in the identification of Mycobacterium spp.
    Collins T; Levett PN
    J Med Microbiol; 1989 Nov; 30(3):175-81. PubMed ID: 2511320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain.
    Shishido Y; Mitarai S; Otomo K; Seki M; Sato A; Yano I; Koyama A; Hattori T
    Int J Tuberc Lung Dis; 2007 Dec; 11(12):1334-8. PubMed ID: 18034955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [NAD(P)-glycohydrolase in tuberculosis bacteria. A contribution to the mechanism of action INH].
    Bartmann K; Coper H; Jütte R
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1967; 257(1):8. PubMed ID: 4385332
    [No Abstract]   [Full Text] [Related]  

  • 38. [Influence of isoniazid complex with A-I apolipoprotein on activity of lysosomal enzymes in mice with tuberculous inflammation model].
    Sumenkova DV; Poliakov LM; Panin LE
    Eksp Klin Farmakol; 2012; 75(11):28-30. PubMed ID: 23323330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antitubercular effect of capreomycin in vitro].
    Janowiec M
    Gruzlica; 1969 Jul; 37(7):629-35. PubMed ID: 4981783
    [No Abstract]   [Full Text] [Related]  

  • 40. [Production and laboratory examination of INH-resistant BCG vaccine].
    Milinković M
    Plucne Bolesti Tuberk; 1971; 23(4):347-53. PubMed ID: 4948961
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.